Medifast (MED) Reports In-Line Q3 EPS, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Medifast (MED) Defended at DA Davidson
November 7, 2018 9:53 AM ESTDA Davidson analyst Linda Bolton Weiser reiterated a Buy rating and $249 price target on Medifast (NYSE: MED) telling clients to buy on today's pull-back.
Weiser commented, "MED reported 3Q18 sales of $139M, above consensus of $125M and guidance of $120M-$125M. Revenue growth... More
